NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, will release its Q4 and full-year 2024 financial results on April 2, 2025, after U.S. market close.
The company will host a conference call and webcast on April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST. CEO Laurent Levy and CFO Bart van Rhijn will present the year-end results and provide a business update for Q4 and full year 2024, followed by a Q&A session.
Nanobiotix (NASDAQ: NBTX), un'azienda biotecnologica in fase avanzata, focalizzata su trattamenti per il cancro basati su nanoparticelle, pubblicherà i suoi risultati finanziari del Q4 e dell'intero anno 2024 il 2 aprile 2025, dopo la chiusura del mercato statunitense.
L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta il 3 aprile 2025, alle 8:00 AM EDT / 2:00 PM CEST. Il CEO Laurent Levy e il CFO Bart van Rhijn presenteranno i risultati di fine anno e forniranno un aggiornamento aziendale per il Q4 e l'intero anno 2024, seguiti da una sessione di domande e risposte.
Nanobiotix (NASDAQ: NBTX), una empresa biotecnológica en etapa clínica avanzada centrada en tratamientos contra el cáncer basados en nanopartículas, publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el 2 de abril de 2025, después del cierre del mercado estadounidense.
La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo el 3 de abril de 2025, a las 8:00 AM EDT / 2:00 PM CEST. El CEO Laurent Levy y el CFO Bart van Rhijn presentarán los resultados de fin de año y ofrecerán una actualización empresarial para el cuarto trimestre y el año completo 2024, seguida de una sesión de preguntas y respuestas.
Nanobiotix (NASDAQ: NBTX), 나노입자 기반 암 치료에 집중하는 후기 임상 단계의 생명공학 회사가 2024년 4분기 및 연간 재무 결과를 2025년 4월 2일 미국 시장 종료 후 발표할 예정입니다.
회사는 2025년 4월 3일 오전 8시 EDT / 오후 2시 CEST에 컨퍼런스 콜 및 웹캐스트를 진행합니다. CEO 로랑 레비와 CFO 바르트 반 라이힌이 연말 결과를 발표하고 2024년 4분기 및 연간 비즈니스 업데이트를 제공한 후 Q&A 세션이 이어집니다.
Nanobiotix (NASDAQ: NBTX), une entreprise de biotechnologie en phase clinique avancée axée sur les traitements du cancer basés sur des nanoparticules, publiera ses résultats financiers du T4 et de l'année complète 2024 le 2 avril 2025, après la clôture du marché américain.
L'entreprise organisera une conférence téléphonique et un webinaire le 3 avril 2025 à 8h00 EDT / 14h00 CEST. Le PDG Laurent Levy et le CFO Bart van Rhijn présenteront les résultats de fin d'année et fourniront une mise à jour sur l'activité pour le T4 et l'année entière 2024, suivis d'une session de questions-réponses.
Nanobiotix (NASDAQ: NBTX), ein biotechnologisches Unternehmen in der späten klinischen Phase, das sich auf nanopartikelbasierte Krebsbehandlungen konzentriert, wird seine Finanzergebnisse für das 4. Quartal und das gesamte Jahr 2024 am 2. April 2025 nach Börsenschluss in den USA veröffentlichen.
Das Unternehmen wird am 3. April 2025 um 8:00 Uhr EDT / 14:00 Uhr CEST eine Telefonkonferenz und einen Webcast veranstalten. CEO Laurent Levy und CFO Bart van Rhijn werden die Jahresergebnisse präsentieren und ein Geschäftsupdate für das 4. Quartal und das gesamte Jahr 2024 geben, gefolgt von einer Frage- und Antwortsitzung.
- None.
- None.
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST
PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, on Wednesday, April 2, 2025, after the close of the U.S. market.
This release will be followed by a conference call and webcast on Thursday, April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial and business officer, will briefly review the Company’s year-end results and provide an update on business activities for the fourth quarter and full year of 2024 before taking questions from participants.
Details of the call are as follows:
Webcast link: click here
Conference call link: click here
Details of the call are also available in the investors section of the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior the event start. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.
Participants are invited to email their questions in advance to investors@nanobiotix.com.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 Investors@nanobiotix.com | |
| Media Relations | ||
| France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Communications nanobiotixteam@uncappedcommunications.com | |
Attachment
FAQ
When will Nanobiotix (NBTX) release its Q4 and full-year 2024 earnings?
What time is the Nanobiotix (NBTX) Q4 2024 earnings call?
Who will present during the NBTX Q4 2024 earnings call?
How can investors submit questions for the NBTX Q4 2024 earnings call?
